Datatop: A multicenter controlled clinical trial in early parkinson's disease: Parkinson study group

Archives of Neurology

Volumn 46, Issue 10, 1989, Pages 1052-1060

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

SELEGILINE; TOCOPHEROL;

ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

COHORT STUDIES; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; MALE; MIDDLE AGE; MULTICENTER STUDIES; PARKINSON DISEASE; PHENETHYLAMINES; RANDOMIZED CONTROLLED TRIALS; SELEGILINE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; VITAMIN E;

EID: 0024457355     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1989.00520460028009     Document Type: Article

References (77)

1. Shoulson I. Experimental therapeutics directed at the pathogenesis of Parkinson's disease. In: Calne DB, ed. Handbook of Experimental Pharmacology: Drugs for the Treatment of Parkinson's Disease. New York, NY: Springer-Verlag NY; 1989;88:289-305.
2. Shoulson I. Protective therapy for Parkinson's disease. In: Koller WC, Paulson G, eds. Therapeutic Approaches to Parkinson's Disease. New York, NY: Marcel Dekker Inc. In press.
3. Shoulson I and the Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). Acta Neurol Scand Suppl. In press.
4. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. J Neural Transm. 1976;38:277-301.
5. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol. 1977;34:33-35.
6. Hornykiewicz O. Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S, eds. Movement Disorders. Stoneham, Mass: Butterworth Publishers Inc; 1982;1:41-58.
7. Cohen G. The pathobiology of Parkinson's disease: Biochemical aspects of dopamine neuron senescence. J Neural Transm. 1983;19(suppl):89-103.
8. Cohen G. Oxidative stress in the nervous system. In: Sies H, ed. Oxidative Stress. Orlando, Fla: Academic Press Inc; 1985:383-402.
9. Robinson DS. Changes in monoamine oxidase and monoamines with human development and aging. Fed Proc. 1975;34:103-107.
10. Cote LJ, Kremzner LT. Biochemical changes in normal aging in human brain. Adv Neurol. 1983;38:19-30.
11. Slivka A, Cohen G. Hydroxyl radical attack on dopamine. J Biol Chem. 1985;260:15466-15472.
12. Johnson G. Studies of the mechanisms of 6-hydroxydopamine cytotoxicity. Med Biol. 1976;54:406-420.
13. Graham DG. Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicology. 1984;5:83-96.
14. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem. 1989;52:381-389.
15. Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione and ascorbic acid in parkinsonian brains. J Neurochem. 1989;52:515-520.
16. Ambani LM, Van Woert WH, Murphy S. Brain peroxidase and catalase in Parkinson's disease. Arch Neurol. 1975;32:114-118.
17. Perry TL, Godin DV, Hansen S. Parkinson's disease: A disorder due to nigral glutathione deficiency? Neurosci Lett. 1982;33:305-310.
18. Kish SJ, Morito C, Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease brain. Neurosci Lett. 1985;58:343-346.
19. Chiba K, Trevor A, Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun. 1984;120:574-578.
20. Vyas I, Heikkila RE, Nicklas WJ. Studies on the neurotoxicity of MPTP: inhibition of MAO-linked substrate oxidation by its metabolite, MPP+. J Neurochem. 1986;46:1501-1507.
21. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983;219:979-980.
22. Burns RS, LeWitt PA, Ebert MH, Pakkenberg H, Kopin IJ. The clinical syndrome of dopamine deficiency: parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N Engl J Med. 1985;312:1418-1421.
23. Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Ann Neurol. 1986;20:449-455.
24. Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR, Felten DL. Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,5,6-tetrahy-dropyridine treatment than young adults. Neurosci Lett. 1986;70:326-331.
25. Langston JW, Irwin I, Langston EB. Pargyline prevents MPTP-induced parkinsonism in primates. Science. 1984;225:1480-1482.
26. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetra-hydropyridine by monoamine oxidase inhibitors. Nature. 1984;311:467-469.
27. Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD. Pargyline and deprenyl prevent the neurotoxicity of MPTP in monkeys. Eur J Pharmacol. 1984;106:209-210.
28. Tanner CM. The role of environmental toxins in the etiology of Parkinson's disease. Trends Neurosci. 1989;12:49-54.
29. Knoll J. Deprenyl (selegiline): the history of its development and pharmacological action. Acta Neurol Scand Suppl. 1983;95:57-80.
30. Riederer P, Youdim MBH. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with L-deprenyl. J Neurochem. 1986;46:1359-1365.
31. Willson RL. Free radical protection: why vitamin E, not vitamin C, beta-carotene or glutathione? In: Porter R, Whelan J, eds. Biology of Vitamin E: Ciba Foundation Symposium 101. London, England: Pitman Books Ltd; 1983:19-44.
32. Halliwell B, Gutteridge JMC. Oxygen radicals and the nervous system. Trends Neurosci. 1985;8:22-26.
33. Eisler T, Calne DB, Ebert MH, et al. Biochemical measurements during (-)deprenyl teratment of parkinsonism. In: Singer TP, Van Korff R, Murphy DL, eds. Monoamine Oxidase: Structure, Function and Altered Functions. Orlando, Fla: Academic Press Inc; 1979:497-505.
34. Csanda E, Tarczy M. Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1983;95:117-122.
35. Kaufmann H, Elizan T, Yahr MD, Moros D, VanWoert M. Deprenyl monotherapy in patients with early Parkinson's disease: A clinical and biochemical study. Neurology. 1989;39(suppl 1):229. Abstract.
36. Fahn S. High-dosage antioxidants in early Parkinson's disease. Arch Neurol. 1988;45:810. Abstract.
37. Golbe LI, Farrell T, Davis PH. Case-control survey of early life dietary factors in Parkinson's disease. Arch Neurol. 1988;45:1350-1353.
38. Tanner CM, Cohen JA, Summerville BC, Goetz CG. Vitamin use and Parkinson's disease. Ann Neurol. 1988;24:182. Abstract.
39. Birkmayer W, Knoll J, Riederer P, Youdim MBH. Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry. 1983;19:170-176.
40. Birkmayer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study. J Neural Transm. 1985;64:113-127.
41. Cox DR, Oakes D. The Analysis of Survival Data. London, England: Chapman & Hall Ltd; 1984.
42. Quinn N, Critchley P, Parkes D, Marsden CD. When should levodopa be started? Lancet. 1986;2:985-986.
43. Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ, Donaldson MC, eds. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E & S Livingstone: 1969:152-157.
44. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of Neurologic Deficit. Woburn, Mass: Butterworths; 1989;285-309.
45. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
46. Shoulson I, Kurlan R, Rubin A, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington's disease as a prototype. In: Munsat TL, ed. Quantification of Neurologic Deficit. Woburn, Mass: Butterworths; 1989:271-284.
47. Webster DD. Critical analysis of disability in Parkinson's disease. Mod Treatment. 1968;5:257-282.
48. Cassell K, Shaw K, Stern G. A computerized tracking technique for the assessment of motor disabilities. Brain. 1973;96:815-826.
49. Folstein MF, Folstein SE, McHugh P. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
50. Wechsler D. Wechsler Adult Intelligence Scale, Revised Manual. New York, NY: The Psychological Corp; 1981.
51. Smith A. Symbol Digit Modalities Test. Los Angeles, Calif: Western Psychological Services; 1973.
52. Buschke H, Fuld PA. Evaluating storage, retention and retrieval in disorders of memory and learning. Neurology. 1974;24:1019-1025.
53. Flowers KA, Robertson C. The effect of Parkinson's disease on the ability to maintain a mental set. J Neurol Neurosurg Psychiatry. 1985;48:517-529.
54. Albert M, Moss M. The assessment of memory disorders in patients with Alzheimer's disease. In: Squire L, Butters N, eds. Neuropsychology of Memory. New York, NY: Guilford Press; 1984:236-246.
55. Benton A. Multi-lingual aphasia examination. Neuropsychologia. 1967;5:135-140.
56. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
57. Williams JBN. A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry. 1988;45:742-747.
58. Stampfer MJ, Buring JE, Wilett W, Rosner B, Eberlein K, Hennekens CH. The 2 ×2 factorial design: its appliction to a randomized trial of aspirin and carotene in U.S. physicians. Statistics Med. 1985;4:111-116.
59. Moscucci M, Byrne L, Weintraub M, Cox C. Blinding, unblinding, and the placebo effect: An analysis of patients guesses of treatment assignment in a double-blind clinical trial. Clin Pharmacol Ther. 1987;41:259-265.
60. Goetz CG, Tanner CM, Shannon KM. Progression of Parkinson's disease without levodopa. Neurology. 1987;37:695-698.
61. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981:260-280.
62. Cox DR. Regression models and life tables. JR Stat Soc B. 1972;34:187-220.
63. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient, II: Analysis and examples. Br J Cancer. 1976;35:1-39.
64. Craft NE, Brown ED, Smith JC. Effects of storage in handling on concentrations of individual carotenoids, retinol and tocopherol in plasma. Clin Chem. 1988;34:44-48.
65. Beckett AH, Tucker GT, Moffat AC. Routine detection and identification in urine of stimulants and other drugs, some of which may be used to modify performance in sport. J Pharm Pharmacol. 1967;19:273-294.
66. Yahr MD. Levodopa. Ann Intern Med. 1975;83:677-682.
67. Stern GM, Lees AJ, Hardie R, Sandler M. Clinical and pharmacological aspects of (-) deprenyl treatment in Parkinson's disease. Mod Probl Pharmacopsychiatry. 1983;19:215-219.
68. Kopin IJ, Polinsky RJ, Oliver JA, Oddershede IR, Ebert MH. Urinary catecholamine metabolites distinguish different types of sympathetic neuronal dysfunction in patients with orthostatic hypotension. J Clin Endocrinol Metab. 1983;57:632-637.
69. Sandler M, Stern GM. Deprenyl in Parkinson disease. In: Marsden CD, Fahn S, eds. Movement Disorders. Woburn, Mass: Butterworths; 1982;2:166-173.
70. Machlin LJ, Gabriel E. Kinetics of tissue alpha-tocopherol uptake and depletion following administration of high levels of vitamin E. Ann NY Acad Sci. 1982;393:48-60.
71. Evans P, Linsner M, Shoulson I. Computer application to handle centralized pharmacy dispensing for multi-institutional Parkinson study. Controlled Clin Trials. 1988;9:275. Abstract.
72. Lewin R. Clinical trial for Parkinson's disease? Science. 1985;230:527-528.
73. Martilla RJ. Epidemiology. In: Koller WC, ed. Handbook of Parkinson's Disease. New York, NY: Marcel Dekker Inc; 1987:35-50.
74. Jenkins AC. Epidemiology of Parkinson's disease in Victoria. Med J Aust. 1966;2:496-502.
75. Rosati G, Granieri E, Pinna L, et al. Risk of Parkinson disease in Mediterranean people. Neurology. 1980;30:250-255.
76. Schoenberg BS, Anderson DW, Haerer AF. Prevalence of Parkinson's disease in the biracial population of Copiah County, Mississippi. Neurology. 1985;35:841-845.
77. Li S, Schoenberg BS, Wang C, et al. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch Neurol. 1985;42:655-657.